Pancreatic cancer is a grave malignancy showing an upward trend
in morbidity and mortality during the recent decades. For reasons of late
diagnosis, chemo-resistance, low potential resect able rate and high
post-operative recurrence rate, it has been the 6th most common cause of cancer
death in China.
As one of the most aggressive malignancies and the most
common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) represents a significant
therapeutic challenge. Conventional chemotherapeutic cytotoxic agents are
proved to be with a poor survival benefit.
Though the current first-line therapy FOLFIRINOX increased
the median survival time compared with gemcitabine, it has been still
unsatisfactory. Another direction enlighten by the treatment experience in
other tumours is targeting certain molecules that participate in specific
signalling pathways mediating cancer cell proliferating, angiogenesis,
chemo-resistance or metastasis.
No comments:
Post a Comment